Thank morning, everyone, the you to your We'd thank you, Susan. us. questions. devote of to today time Good for like most joining and
So, We I'll our XXXX. we proud with begin for both as remarks in brief and and throughout investors. our made team positions perform continue deliver, remain they to of even XXXX success business greater recent patients today's that cover progress for prepared our discussion highlights. the The us
therapies couldn't patient be that position ability of the year for pain improve portfolio a value-driving the healthcare with best-in-class year excited of and milestones or more provide series safe, pathway. low products diversified have along we future the unique, a We strong no-opioid to We providers' of to in the a neural experiences in ended support Pacira. ahead,
also ZILRETTA $XXX EXPAREL potential while gives With knee in of Our high-potential, prospects have for management. increasing more than contribution innovation achievements a an of pain, chronic in us an in pipeline great us significant complimentary moving commercial the Pacira long-term ZILRETTA exciting in its highlighted for Flexion, greater treatment with osteoarthritis of for sales pain. product and asset opioid-sparing in highly durable and placed in million that a as pain growing provides forefront a Pacira. even sales, the our the confidence presence of by acquisition XXXX, forward, XXXX,
this acquisition Importantly, provide revenue will our earnings. we we meaningful expect our it and flows enhances diversifies to to synergies as our near substantial line. top stream, drive long-term believe accretion cash and And
Over of have with United progress launch, with I'll exciting very Turning milestone. million we a recent now made XX been EXPAREL. patients alone. achievement in to with treated States the start the since EXPAREL,
Our accomplishments. record million, sales team with margins XXXX, up $XXX eighth are our important adjusted XX% consecutive EXPAREL of EBITDA. in adjusted These achieved year EBITDA positive of marking
which EXPAREL-based blocks developing been revolution, are outcomes. anesthesia have perfecting As enabling reiterating, our we the blocks, using new and number driver. to patient are ensure is one imaging growth successful blocks, regional anesthesiologists Regional old
all Our best-practice helping Facility patient the surgical market sites transfer, and knowledge state-of-the-art [Ph] is to this [PITT] care. and is supporting real-time migration transition Training accelerate of Innovation with
anticipated. bigger excited year, we will there impact an Book patents in were are Book for EXPAREL which In Book. be we are Orange Orange all of addition, Patent the total with EXPAREL market, new will January Recently, allowance notices XX, Book EXPAREL in we submit fortified launch four that U.S. six we two XXXX. the of after of the a making patents our we Last These the Office. estate Orange in Trademark expiration listing, now to pediatrics dates Orange throughout composition significantly that listed composition FDA are with listed IP received even XXXX, from new than patents where
the costly displacing blocks tight-knit group ESP or care, a and procedures. is and and catheters. are cumbersome triggering surgeons us regional technique recovery as and a of best spinae We same spinae are an surgeons, for an establish adult for effect pediatric seeing surgeries. erector provides with pediatric pathways adults. Spine block halo of erector ESP blocks the adult EXPAREL to in the opportunity pumps likeminded cornerstone and is practice, spine becoming spine Interestingly, of and for the children standard enhance both This
for underway. that report expansion delighted launch international now our to to are is targeted European Looking EXPAREL, our we
to call key points, This includes lower gain ability you will field blocks, traction help and nerve as enjoys and label into extremity as having a important both or to as our access. this may without Importantly, simplify should which and blocks blocks, such transverse broad well in in recall, as is plane market field factor TAP. EXPAREL our Europe, expand upper abdominis market
outcomes Our C-sections which procedures rapidly and opportunity women's X.X C-section opioid-sparing means U.S. procedures improvement control procedures. XX% over year. EXPAREL recovery demand pain mothers. prior positive the breast EXPAREL seen given are to health not oncology driving significant this success, is million continued for franchise and expanding in blocks see driving proposition, the experience gynecologic the incredible TAP year With value faster has C-section EXPAREL are Further, we growth. in in per penetration, the new and in for in surprising
positive care This EXPAREL, plastic, optimizing CEOs an better the With demand other patients. needs the able the while EXPAREL need women protocols. multimodal expedite escalated don't now year, the opioid-sparing using experience of procedures. the stay pain of are EXPAREL-based are ERAS their want to to with who they many through drive in experience oncology meet mothers past and to know, overnight all and management opioid-free simultaneously for their discharge lifetime hospital, experience has COVID household, will a surgeons of birth we a for for decision-making As and breast,
use a in iovera and Canada, also only to In not where be in the handheld resources iovera to Pacira franchises, is could in great of option U.K. ZILRETTA addition available and EXPAREL the our with institutional a settings design EU. and franchise; success allowing with previously console-based XXXX, in launched strides iovera In of you our the systems. growing cryotherapy available a partner we with variety the cryoanalgesia making environments used it we are and
also used design We and for medial indications. to We next-generation develop studies block have more a new tip treatment a year human additional as pilot device, as a user-friendly, chronic ready pain. branch an now SmartTips specific opportunity for low-back for last
preparing also a are treatment to iovera very spasticity, a as represents We evaluate significant opportunity. which long-term for
in submission year's and clinical studies year with and and of in have extremity deliver STRIDE build or significant lower $XXX record Looking Pacira last two XXXX. X Phase updates. ahead, to the market, another COVID-related quarter banner the least XXXX upper of regulatory million will a EXPAREL growth, fourth addressable progressing lower the year, the significant approximately nerve block to nerve Enrollment and expect of extremity year timing fourth as as We extremity we be million. the expected label to last of multiple success, a at we quarter for procedures as expect delays around block believe our EBITDA of year is on believe sNDA the market sales, here our is studies. shifted an
to alignment. XXXX, first focusing on and for the only are FDA obtain osteoarthritis areas in pain, with we the For development three will of treatment ZILRETTA, be meeting knee FDA-approved and
to expect osteoarthritis first-choice will pain to knee. corticosteroid the superiority establish current we is The for first which label safety ZILRETTA the of claim include diabetes, as a expand in
perfect will shoulder significantly the Pacira Phase a In launch plan short the And well distributors stocking believe of materials. we to is the longer-term are unique year-end. expand family we ZILRETTA include and working of same preparing are its begin a lastly, dosing. clinical expand issues we which knee use. indication At And in data Second, X time, short, fit are to study, we several we with we to envision to specialty current repeat as products. our addressing pharmacies, as previously capabilities and commercial for
have to processes issues these our the of these moving are the by many to end We systems and second of expect operations, us quarter. behind Pacira and
on of of launch EXPAREL iovera and procedural we now which interim weeks. TKA the for in a few device and next study, is PREPARE is evaluating as an in underway, iovera, For next-generation our the track combination the procedures of remain handheld our solution review
opportunity we I for mentioned the As spasticity. earlier, are in excited particularly
shared our event patients. may compelling You that analyst Paul recall proof-of-concept spasticity some in last videos Winston Dr. year, at
we of to pathway limited use. ease with Importantly, already to working the costly is work a We the often and label. and currently for associated pain spasticity have And facilitate Patients regulatory FDA on-label. are plan with therapeutic treatment define greater spasticity of iovera our safety, to adoption efficacy, options. given to adding
example, which Botox patients has are For dose receiving limitation.
a treatments to three-four for received year patients treatment. per $XXXX $XXXX Here
shown with iovera highly great example spasticity. has a tips is outcomes Phenol adjacent costing variable. could are contrast, the in iovera represent And value to has painful, scarring a $XXX, that indication. phenol, use neurolytic. in this proposition Another $XXX tremendous of chemical requires With and promise anesthesia, is tissue
and ZILRETTA, includes EXPAREL, portfolio to addition iovera, opportunities. stage In promising our early
We expect late multivesicular initiate technology analgesia of Phase to study in liposome a XXXX. X subarachnoid for our
are cardiac sorry iovera following am as use stellate evaluate separately for I pilot We dysrhythmia ganglion planning to EXPAREL -- surgery. studies spasticity and in blocks heart
formulation defining our for days low In we multivesicular acting more. management for bupivacaine for of five are or addition, back and next and in inflammation dexamethasone longer pain multi-modal dose steps high pain -- our programs liposome of clinical
improvements areas business to innovate patients indications, including of our will the expansion, at continue design Moving new ahead more. and forefront with line always Pacira all endeavors, in of
last We healthcare our are facility With our to hands to innovations and provider of we accomplished highlights. turn center more year excited that, a state-of-the-art will partners. I'll that in all for even I over what's call into out PITT to leverage in PITT the financial Charlie? as building some proud training we as Tampa bring innovation these and Charlie of second the am well Houston for come.
